Structure Therapeutics Inc. (NASDAQ:GPCR) Position Increased by abrdn plc

abrdn plc increased its position in shares of Structure Therapeutics Inc. (NASDAQ:GPCR - Free Report) by 132.7% in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 217,083 shares of the company's stock after purchasing an additional 123,789 shares during the quarter. abrdn plc owned approximately 0.47% of Structure Therapeutics worth $9,528,000 as of its most recent filing with the SEC.

Other large investors have also recently made changes to their positions in the company. FORA Capital LLC purchased a new stake in Structure Therapeutics in the 1st quarter valued at $732,000. Capital International Investors grew its holdings in shares of Structure Therapeutics by 50.8% during the 1st quarter. Capital International Investors now owns 1,281,564 shares of the company's stock worth $54,928,000 after purchasing an additional 431,540 shares during the period. Capital Research Global Investors grew its holdings in shares of Structure Therapeutics by 56.9% during the 1st quarter. Capital Research Global Investors now owns 1,527,483 shares of the company's stock worth $65,468,000 after purchasing an additional 553,948 shares during the period. Altitude Crest Partners Inc. purchased a new position in shares of Structure Therapeutics during the 1st quarter worth $8,793,000. Finally, Bellevue Group AG lifted its stake in Structure Therapeutics by 2,858.7% during the 1st quarter. Bellevue Group AG now owns 363,926 shares of the company's stock worth $15,598,000 after acquiring an additional 351,626 shares in the last quarter. 91.78% of the stock is currently owned by hedge funds and other institutional investors.

Structure Therapeutics Stock Down 0.0 %

Shares of NASDAQ GPCR traded down $0.01 on Friday, hitting $41.14. The company had a trading volume of 699,360 shares, compared to its average volume of 682,974. Structure Therapeutics Inc. has a 12-month low of $26.61 and a 12-month high of $74.21. The business has a 50 day moving average of $39.57 and a two-hundred day moving average of $39.79. The firm has a market capitalization of $2.35 billion, a P/E ratio of -54.85 and a beta of -3.22.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.23) by $0.05. On average, sell-side analysts anticipate that Structure Therapeutics Inc. will post -0.79 earnings per share for the current year.

Wall Street Analysts Forecast Growth

GPCR has been the topic of several research analyst reports. JMP Securities cut their target price on Structure Therapeutics from $91.00 to $86.00 and set a "market outperform" rating on the stock in a research report on Friday, August 9th. Cantor Fitzgerald reiterated an "overweight" rating and issued a $65.00 target price on shares of Structure Therapeutics in a research note on Monday, September 23rd. Finally, Morgan Stanley initiated coverage on Structure Therapeutics in a research note on Monday, September 23rd. They issued an "overweight" rating and a $118.00 target price on the stock. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has an average rating of "Buy" and an average target price of $86.80.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.